This document provides an overview of cystic fibrosis pathophysiology and treatments. It discusses traditional therapies such as inhaled DNase and hypertonic saline as well as newer CFTR modulator therapies. Most notably, it outlines the development of ivacaftor for G551D mutations in 2012 and its approval for additional mutations. It also discusses lumacaftor-ivacaftor and tezacaftor-ivacaftor combinations for treating the F508del mutation, representing progress toward treating the underlying cause of cystic fibrosis. Overall, the document traces the story of cystic fibrosis treatment from 1950 to present day and provides optimism about continued therapeutic advances.